Real Time Ultrasound Molecular Imaging of Prostate Cancer with PSMA-targeted Nanobubbles

Overview

Journal Nanomedicine

Publisher Elsevier

Specialties Biomedical Engineering
Biotechnology

Date 2020 Apr 30

PMID 32348874

Citations 28

Authors

Reshani H Perera

Al de Leon

Xinning Wang

Yu Wang

Gopal Ramamurthy

Pubudu Peiris

Eric Abenojar

James P Basilion

Agata A Exner

Affiliations

Soon will be listed here.

Abstract

Contrast-enhanced ultrasound with microbubbles has shown promise in detection of prostate cancer (PCa), but sensitivity and specificity remain challenging. Targeted nanoscale-contrast agents with improved capability to accumulate in tumors may result in prolonged signal enhancement and improved detection of PCa with ultrasound. Here we report nanobubbles (NB) that specifically targets prostate specific membrane antigen (PSMA) overexpressed in PCa. The PSMA-targeted-NB (PSMA-NB) were utilized to simultaneously image dual-flank PCa (PSMA-positive PC3pip and PSMA-negative PC3flu) to examine whether the biomarker can be successfully detected and imaged in a mouse model. Results demonstrate that active targeting rapidly and selectively enhances tumor accumulation and tumor retention. Importantly, these processes could be visualized and quantified, in real-time, with clinical ultrasound. Such demonstration of the immense yet underutilized potential of ultrasound in the molecular imaging area can open the door to future opportunities for improving sensitivity and specificity of cancer detection using parametric NB-enhanced ultrasound imaging.

Citing Articles

Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.

Fang J, Alhaskawi A, Dong Y, Cheng C, Xu Z, Tian J J Zhejiang Univ Sci B. 2025; 26(2):124-144.

PMID: 40015933 PMC: 11867783. DOI: 10.1631/jzus.B2300614.

Assessing Therapeutic Nanoparticle Accumulation in Tumors Using Nanobubble-Based Contrast-Enhanced Ultrasound Imaging.

Cooley M, Wegierak D, Perera R, Abenojar E, Nittayacharn P, Berg F ACS Nano. 2024; 18(48):33181-33196.

PMID: 39566912 PMC: 11619768. DOI: 10.1021/acsnano.4c11805.

Nanobubble Contrast Enhanced Ultrasound Imaging: A Review.

Wegierak D, Nittayacharn P, Cooley M, Berg F, Kosmides T, Durig D Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(6):e2007.

PMID: 39511794 PMC: 11567054. DOI: 10.1002/wnan.2007.

Bibliometric and scientometric analysis of PSMA-targeted radiotheranostics: knowledge mapping and global standing.

Sallam M, Mohammadi M, Sainsbury F, Nguyen N, Kimizuka N, Muyldermans S Front Oncol. 2024; 14:1397790.

PMID: 39011478 PMC: 11246987. DOI: 10.3389/fonc.2024.1397790.

Preparation of Hematoporphyrin-Poly(Lactic Acid) Nanoparticles Encapsulated Perfluoropentane/Salicylic Acid for Enhanced US/CEST MR Bimodal Imaging.

Ding L, Xu F, Luo B, Cheng L, Huang L, Jia Y Int J Nanomedicine. 2024; 19:4589-4605.

PMID: 38799695 PMC: 11127694. DOI: 10.2147/IJN.S454486.

References

Perera R, Wu H, Peiris P, Hernandez C, Burke A, Zhang H . Improving performance of nanoscale ultrasound contrast agents using N,N-diethylacrylamide stabilization. Nanomedicine. 2016; 13(1):59-67. PMC: 5237399. DOI: 10.1016/j.nano.2016.08.020. View

Segers T, Lohse D, Versluis M, Frinking P . Universal Equations for the Coalescence Probability and Long-Term Size Stability of Phospholipid-Coated Monodisperse Microbubbles Formed by Flow Focusing. Langmuir. 2017; 33(39):10329-10339. DOI: 10.1021/acs.langmuir.7b02547. View

Zlitni A, Yin M, Janzen N, Chatterjee S, Lisok A, Gabrielson K . Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. PLoS One. 2017; 12(5):e0176958. PMC: 5417523. DOI: 10.1371/journal.pone.0176958. View

Pallwein L, Mitterberger M, Pelzer A, Bartsch G, Strasser H, Pinggera G . Ultrasound of prostate cancer: recent advances. Eur Radiol. 2007; 18(4):707-15. DOI: 10.1007/s00330-007-0779-7. View

Genady A, Janzen N, Banevicius L, El-Gamal M, El-Zaria M, Valliant J . Preparation and Evaluation of Radiolabeled Antibody Recruiting Small Molecules That Target Prostate-Specific Membrane Antigen for Combined Radiotherapy and Immunotherapy. J Med Chem. 2016; 59(6):2660-73. DOI: 10.1021/acs.jmedchem.5b01881. View

Ristau B, OKeefe D, Bacich D . The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2013; 32(3):272-9. PMC: 3972351. DOI: 10.1016/j.urolonc.2013.09.003. View

Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, Godehardt E . Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015; 68(4):713-20. DOI: 10.1016/j.eururo.2015.06.008. View

Olcum S, Cermak N, Wasserman S, Christine K, Atsumi H, Payer K . Weighing nanoparticles in solution at the attogram scale. Proc Natl Acad Sci U S A. 2014; 111(4):1310-5. PMC: 3910582. DOI: 10.1073/pnas.1318602111. View

Cronin K, Lake A, Scott S, Sherman R, Noone A, Howlader N . Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018; 124(13):2785-2800. PMC: 6033186. DOI: 10.1002/cncr.31551. View

10.

Hernandez C, Abenojar E, Hadley J, De Leon A, Coyne R, Perera R . Sink or float? Characterization of shell-stabilized bulk nanobubbles using a resonant mass measurement technique. Nanoscale. 2019; 11(3):851-855. PMC: 6350620. DOI: 10.1039/c8nr08763f. View

11.

Ghosh A, Heston W . Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004; 91(3):528-39. DOI: 10.1002/jcb.10661. View

12.

Wang X, Huang S, Heston W, Guo H, Wang B, Basilion J . Development of targeted near-infrared imaging agents for prostate cancer. Mol Cancer Ther. 2014; 13(11):2595-606. PMC: 4472004. DOI: 10.1158/1535-7163.MCT-14-0422. View

13.

Maeda H, Bharate G, Daruwalla J . Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2008; 71(3):409-19. DOI: 10.1016/j.ejpb.2008.11.010. View

14.

Wang L, Li L, Guo Y, Tong H, Fan X, Ding J . Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer. Prostate. 2013; 73(11):1147-58. DOI: 10.1002/pros.22663. View

15.

Perner S, Hofer M, Kim R, Shah R, Li H, Moller P . Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007; 38(5):696-701. DOI: 10.1016/j.humpath.2006.11.012. View

16.

Castanares M, Mukherjee A, Chowdhury W, Liu M, Chen Y, Mease R . Evaluation of prostate-specific membrane antigen as an imaging reporter. J Nucl Med. 2014; 55(5):805-11. PMC: 4074907. DOI: 10.2967/jnumed.113.134031. View

17.

Hobbs S, Monsky W, Yuan F, ROBERTS W, Griffith L, Torchilin V . Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998; 95(8):4607-12. PMC: 22537. DOI: 10.1073/pnas.95.8.4607. View

18.

Afshar-Oromieh A, Haberkorn U, Schlemmer H, Fenchel M, Eder M, Eisenhut M . Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013; 41(5):887-97. DOI: 10.1007/s00259-013-2660-z. View

19.

Abou-Elkacem L, Bachawal S, Willmann J . Ultrasound molecular imaging: Moving toward clinical translation. Eur J Radiol. 2015; 84(9):1685-93. PMC: 4545409. DOI: 10.1016/j.ejrad.2015.03.016. View

20.

Lee E, Kim A, Oh Y, Kim C . Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials. 2004; 26(2):205-10. DOI: 10.1016/j.biomaterials.2004.02.020. View